伊利替康联合替吉奥在晚期结直肠癌治疗的临床研究

目的 评价晚期结直肠癌患者采用伊立替康联合替吉奥治疗的临床疗效。方法 选取2015年4月~2017年12月我院肿瘤科收治的60例晚期初治结直肠癌患者作为研究对象，根据治疗方案的不同分为联合治疗组（32例）和对照组（28例）。对照组采用伊立替康治疗方案，在对照组基础上联合治疗组联合替吉奥治疗方案，比较两组的不良反应发生率及疗效情况。结果 治疗后，联合治疗组的临床有效率高于对照组，差异有统计学意义(P＜0.05)；两组患者的主要不良反应比较，联合治疗组白细胞减少及胃肠道反应发生率较对照组降低，差异具有统计学意义(P＜0.05)。结论 晚期结直肠癌患者采用伊立替康联合替吉奥治疗方案优于单独采用伊立替康治疗方案，提高临床治疗的有效率，降低白细胞减少及胃肠道等不良反应的发生率。

Clinical Study of Irinotecan Combined with Tegafur,Gimeracil and Oteracil Porassium Capsulesin the Treatment of Advanced Colorectal Cancer

Objective To evaluate the clinical efficacy of irinotecan plusTegafur,Gimeracil and Oteracil Porassium Capsulesin patients with advanced colorectal cancer.Methods 60 patients with advanced primary colorectal cancer admitted to our department of oncology from April 2015 to December 2017 were enrolled in the study. They were divided into the combination treatment group (32 cases) and the control group (28 cases).The control group was treated with irinotecan. On the basis of the control group, the combined treatment group was treated with a combination of Tegafur,Gimeracil and Oteracil Porassium Capsulesand the incidence of adverse reactions and efficacy were compared between the two groups. Results After treatment, the clinical effective rate in the combined treatment group was higher than that in the control group, the difference was statistically significant (P<0.05). The main adverse reactions in the two groups were compared with the leukopenia in the combined treatment group. The incidence of gastrointestinal reactions was lower than that of the control group,the difference was statistically significant (P<0.05). Conclusion The treatment of irinotecan plus Tegafur,Gimeracil and Oteracil Porassium Capsules in patients with advanced colorectal cancer is superior to irinotecan alone in improving the efficiency of clinical treatment and reducing the incidence of leukopenia and gastrointestinal reactions.